IDYA IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.

$23.81  -0.19 (-0.79%)
As of 11/26/2021 13:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/23/2019
Outstanding shares:  38,497,331
Average volume:  267,972
Market cap:   $923,935,944
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45166A102
ISIN:        US45166A1025
Sedol:      BK0VHF6
Valuation   (See tab for details)
PE ratio:   -24.99
PB ratio:   2.88
PS ratio:   17.92
Return on equity:   -16.22%
Net income %:   -99.94%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy